Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

麻省理工学院Broad研究所、哈佛大学和赛勒斯生物技术公司的研究人员现在已经设计了两种CRISPR核酸酶，Cas9和Cas12，以掩盖它们对免疫系统的影响。该团队确定了每个核酸酶上触发免疫系统的蛋白质序列，并使用计算建模来设计逃避免疫识别的新版本。与小鼠的标准核酸酶相比，工程酶具有相似的基因编辑效率和降低的免疫反应。